8-K: Enhabit Announces Preliminary Q2 2024 Results, Showing Continued Business Stabilization

Enhabit released preliminary second quarter 2024 results, indicating continued business stabilization with improved operational performance and debt reduction.

Summary

• Enhabit has released preliminary unaudited results for the second quarter of 2024, showing an adjusted EBITDA in the range of $24.5 million to $25.0 million.
• The company reduced its bank debt by $15 million, including a $10 million payment on its revolving credit facility.
• 43% of Enhabit's non-Medicare visits are now under payor innovation contracts with improved rates, up from 38% in the first quarter of 2024.
• Home health admissions increased by 6.4% year-over-year, driven by non-Medicare admissions.
• The hospice segment achieved monthly sequential growth in average daily census for the fifth consecutive month in June.
• Home health cost per visit came in better than expected, and hospice cost per day decreased sequentially as census grew.
• The second quarter of 2024 is on track to be Enhabit's third consecutive quarter of business stabilization.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's strong operational performance, debt reduction, and cost management. The preliminary results are encouraging, and the management commentary is optimistic.

Positives

• The company is showing strong operational execution with a 6.4% year-over-year increase in home health admissions.
• Enhabit is successfully shifting non-Medicare visits to payor innovation contracts at improved rates.
• The company is actively managing costs, with home health cost per visit better than expected and hospice cost per day decreasing.
• The company has achieved five consecutive months of growth in hospice average daily census.
• The company is making progress on debt reduction with a $15 million reduction in bank debt.

Negatives

• The results are preliminary and unaudited, and the final results may vary materially.
• The company is unable to reconcile the preliminary adjusted EBITDA to GAAP measures without unreasonable effort.

Risks

• Actual results may differ materially from the preliminary results due to the completion of financial close procedures and final accounting adjustments.
• The preliminary results are not necessarily indicative of future performance.
• The company faces risks related to regulatory changes, reimbursement rates, economic conditions, and the ability to attract and retain key personnel.
• There are risks associated with potential disruptions to information systems and the outcome of litigation.

Future Outlook

The company expects to report actual second quarter 2024 financial results on August 6, 2024, and host a webcast and conference call on August 7, 2024. The company believes it is on track for its third consecutive quarter of business stabilization and is positioning itself for profitable growth.

Management Comments

• The strong start to 2024 extended in Q2 as our teams successfully executed on our operational strategies.
• In our home health segment, our 6.4% year-over-year increase in admissions continues to be driven by non-Medicare admissions, and our teams are doing a good job managing our visits per episode and creating additional capacity for growth.
• In our hospice segment, we achieved monthly sequential growth in average daily census in June for the fifth consecutive month.
• We also continue to closely monitor and manage our costs with our home health cost per visit coming in better than expected and hospice cost per day decreasing sequentially as census continued to grow.
• Overall, the second quarter of 2024 is on track to mark Enhabit's third consecutive quarter of business stabilization and successfully positioning the Company for profitable growth.

Industry Context

The announcement reflects a trend in the home health and hospice industry towards managing costs and improving operational efficiency. The shift to payor innovation contracts is a common strategy to improve reimbursement rates. The focus on non-Medicare admissions suggests a strategic move to diversify revenue streams.

Comparison to Industry Standards

• While specific competitor data is not provided, the reported 6.4% year-over-year increase in home health admissions is a positive sign, as many home health companies are struggling with admissions growth.
• The shift to 43% of non-Medicare visits under payor innovation contracts is a significant achievement, as many companies are still working to negotiate better rates with payers.
• The sequential growth in hospice average daily census for five consecutive months is a strong indicator of market share gains, as many hospice providers are facing challenges in census growth.
• The company's focus on cost management, with home health cost per visit better than expected and hospice cost per day decreasing, is in line with industry best practices.

Legal Proceedings

• The company is involved in a lawsuit, Enhabit, Inc. et al. v. Nautic Partners IX, L.P., et al., in which it has asserted claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity.

Stakeholder Impact

• Shareholders should be encouraged by the positive preliminary results and the company's focus on profitable growth.
• Employees may be positively impacted by the company's improved performance and stability.
• Customers should benefit from the company's focus on delivering quality care.
• Creditors should be reassured by the company's debt reduction efforts.

Next Steps

• The company plans to report actual second quarter 2024 financial results on August 6, 2024.
• The company will host a webcast and conference call on August 7, 2024, to discuss the Q2 2024 results.

Key Dates

Keywords

Enhabit, Home Health, Hospice, EBITDA, Debt Reduction, Payor Innovation, Admissions, Cost Management, Preliminary Results, Financial Results